Published in Gene Therapy Weekly, November 9th, 2000
ISIS 104838, an inhibitor of TNF-alpha, has enhanced properties as it employs Isis' proprietary second-generation antisense chemistry, which is more potent than first generation chemistries. The clinical program for ISIS 104838 will investigate the safety and efficacy of the drug administered intravenously (IV) and subcutaneously.
Oral formulations of ISIS 104838 are being developed in parallel by OraSense Ltd., a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.